IMI 2 topics previously advertised as being part of Call 2 now form Calls 3 and 4

The Innovative Medicines Initiative (IMI) informs that the topics previously advertised as being part of IMI 2 - Call 2 will now form IMI 2 - Calls 3 and 4, which are scheduled to be launched simultaneously in December 2014. The seven topics remain the same.

These six research and innovation topics will form IMI 2 - Call 3:
• Remote assessment of disease and relapse (RADAR), topic 1: central nervous system (CNS);
• Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification;
• Linking clinical neuropsychiatry and quantitative neurobiology;
• The consistency approach to quality control in vaccine manufacture;
• Pertussis vaccination research;
• Knowledge Repository to enable patient focused medicine development.

IMI 2 - Call 4 will include one Coordination and Support Action:
• Enabling platform on medicines adaptive pathway to patients.
All information regarding future IMI Call topics is indicative and subject to change. Final information about the IMI’s future Calls will be communicated after approval by the IMI Governing Board.  

The goal of the IMI 2 programme is to develop next generation vaccines, medicines and treatments, such as new antibiotics. It will build on the successes and lessons learnt under IMI's first phase. As before, it will bring together companies, universities, public laboratories, innovative small and medium-sized enterprises (SMEs), patient groups and regulators in collaborative projects that will pave the way for breakthrough vaccines, medicines and treatments to tackle Europe’s growing health challenges, and secure the future international competitiveness of Europe’s pharmaceutical industry.